Evidence map›Paper›PMID 31921964›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2019

Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice.

Zhenyou Zou, Shengxi Shao, Ruyi Zou, Jini Qi, Liguan Chen, Hui Zhang, Qiqiong Shen, Yue Yang, Liman Ma, Ruzeng Guo and 42 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Epigenetics in Alzheimer's Disease.Frontiers in aging neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors at 8 institutions in 3 countries.

Zhenyou ZouGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Shengxi ShaoDivision of Cell and Molecular Biology, Imperial College London, London, United Kingdom.
Ruyi ZouChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Jini QiMedical School of Taizhou University, Taizhou, ZJ, China.
Liguan ChenZhejiang Armed Police Corps, Hangzhou, ZJ, China.
Hui ZhangChina Tobacco Gene Research Center, Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, HN, China.
Qiqiong ShenMedical School of Taizhou University, Taizhou, ZJ, China.
Yue YangClinical Laboratory Department, Wenzhou Medical University, ZJ, China.
Liman MaMedical School of Taizhou University, Taizhou, ZJ, China.
Ruzeng GuoMedical School of Taizhou University, Taizhou, ZJ, China.
Hongwen LiGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Haibo TianGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Pengxin LiGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Mingfang YuGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Lu WangGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Wenjuan KongGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Caiyu LiGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Zhenhai YuGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Yuping HuangGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Li ChenGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Qi ShaoMedical School of Taizhou University, Taizhou, ZJ, China.
Xinyan GaoMedical School of Taizhou University, Taizhou, ZJ, China.
Xiaolin ChenMedical School of Taizhou University, Taizhou, ZJ, China.
Zhengbo ZhangMedical School of Taizhou University, Taizhou, ZJ, China.
Jianguo YanGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Xiaoyun ShaoGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Ru PanGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Lu XuClinical Laboratory of Jingyou Hospital, Xiaoshan, ZJ, China.
Jing FangMedical School of Taizhou University, Taizhou, ZJ, China.
Lei ZhaoChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Yaohui HuangChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Anqi LiMedical School of Taizhou University, Taizhou, ZJ, China.
Yuchong ZhangMedical School of Taizhou University, Taizhou, ZJ, China.
Wenkao HuangMedical School of Taizhou University, Taizhou, ZJ, China.
Kechun TianMedical School of Taizhou University, Taizhou, ZJ, China.
Minxin HuMedical School of Taizhou University, Taizhou, ZJ, China.
Linchao XieMedical School of Taizhou University, Taizhou, ZJ, China.
Lingbin WuMedical School of Taizhou University, Taizhou, ZJ, China.
Yu WuMedical School of Taizhou University, Taizhou, ZJ, China.
Zhen LuoMedical School of Taizhou University, Taizhou, ZJ, China.
Wenxin XiaoMedical School of Taizhou University, Taizhou, ZJ, China.
Shanshan MaChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Jianan WangChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Kaixin HuangChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Siyuan HeChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Fan YangChemistry Engineering Department, Shangrao Normal University, Shangrao, JX, China.
Shuni ZhouMedical School of Taizhou University, Taizhou, ZJ, China.
Mo JiaMedical School of Taizhou University, Taizhou, ZJ, China.
Hui ZhangPathology Department, Affiliated Hospital of Taizhou University, ZJ, China.
Hongsheng LuPathology Department, Affiliated Hospital of Taizhou University, ZJ, China.
Xinjuan WangMedical School of Taizhou University, Taizhou, ZJ, China.
Jie TanGuangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, GX, China.
Taizhou University · CNGuilin Medical University · CNShangrao Normal University · CNChina Tobacco · CNImperial College London · GBPurdue University West Lafayette · USWenzhou Medical University · CNZhejiang Police College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIron accumulates in the brain during aging, which catalyzes radical formation, causing neuronal impairment, and is thus considered a pathogenic factor in Alzheimer's disease (AD). To scavenge excess iron-catalyzed radicals and thereby protect the brain and decrease the incidence of AD, we synthesized a soluble pro-iron 5-YHEDA peptide. However, the blood-brain barrier (BBB) blocks large drug molecules from entering the brain and thus strongly reduces their therapeutic effects. However, alternative receptor- or transporter-mediated approaches are possible.

methodsA low-density lipoprotein receptor (LDLR)-binding segment of Apolipoprotein B-100 was linked to the 5-YHEDA peptide (bs-5-YHEDA) and intracardially injected into senescent (SN) mice that displayed symptoms of cognitive impairment similar to those of people with AD.

resultsWe successfully delivered 5-YHEDA across the BBB into the brains of the SN mice via vascular epithelium LDLR-mediated endocytosis. The data showed that excess brain iron and radical-induced neuronal necrosis were reduced after the bs-5-YHEDA treatment, together with cognitive amelioration in the SN mouse, and that the senescence-associated ferritin and transferrin increase, anemia and inflammation reversed without kidney or liver injury. DISCUSSION: bs-5-YHEDA may be a mild and safe iron remover that can cross the BBB and enter the brain to relieve excessive iron- and radical-induced cognitive disorders.

Indexed as

Alzheimer's diseaseApoB-100Blood-brain barrierbs-5-YHEDAIronLDLRRadicalsSenescent mouse

Identifiers

PMID31921964
PMCPMC6944740
OpenAlexW2983671937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.